GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmaxis Ltd (OTCPK:PXSLY) » Definitions » Net Margin %

Pharmaxis (Pharmaxis) Net Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Pharmaxis Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Pharmaxis's Net Income for the six months ended in Dec. 2023 was $-3.98 Mil. Pharmaxis's Revenue for the six months ended in Dec. 2023 was $0.00 Mil. Therefore, Pharmaxis's net margin for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Pharmaxis's Net Margin % or its related term are showing as below:

PXSLY' s Net Margin % Range Over the Past 10 Years
Min: -1028.95   Med: -126.47   Max: 88.27
Current: -277.28


PXSLY's Net Margin % is ranked worse than
90.99% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 3.76 vs PXSLY: -277.28

Pharmaxis Net Margin % Historical Data

The historical data trend for Pharmaxis's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaxis Net Margin % Chart

Pharmaxis Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -353.35 -198.39 -44.47 -26.08 -197.05

Pharmaxis Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -152.27 422.79 -380.79 -144.63 -

Competitive Comparison of Pharmaxis's Net Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmaxis's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaxis's Net Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmaxis's Net Margin % distribution charts can be found below:

* The bar in red indicates where Pharmaxis's Net Margin % falls into.



Pharmaxis Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Pharmaxis's Net Margin for the fiscal year that ended in Jun. 2023 is calculated as

Net Margin=Net Income (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-7.624/3.869
=-197.05 %

Pharmaxis's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-3.982/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmaxis  (OTCPK:PXSLY) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Pharmaxis Net Margin % Related Terms

Thank you for viewing the detailed overview of Pharmaxis's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaxis (Pharmaxis) Business Description

Traded in Other Exchanges
Address
20 Rodborough Road, Locked Bag 5015, Frenchs Forest, Sydney, NSW, AUS, 2086
Syntara Ltd Formerly Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.

Pharmaxis (Pharmaxis) Headlines